ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,144.13
0.00%
Dow Jones
37,815.92
-1.49%
Gold vs US Dollar
2,287.18
-0.20%
Brent Oil
85.475
-0.49%
Bitcoin
58,105.51
-4.14%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Okyo Pharma Limited (OKYO)

  7. Okyo Pharma Limited (OKYO) News

Okyo Pharma (OKYO)

Okyo Pharma Limited
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:OKYO
DateTimeSourceHeadlineSymbolCompany
30/04/202412:00UK RegulatoryOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)LSE:OKYOOkyo Pharma Limited
09/04/202400:00UK RegulatoryOKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024LSE:OKYOOkyo Pharma Limited
02/04/202412:00UK RegulatoryOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryLSE:OKYOOkyo Pharma Limited
22/03/202411:00UK RegulatoryOKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101LSE:OKYOOkyo Pharma Limited
21/03/202411:00UK RegulatoryOKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialLSE:OKYOOkyo Pharma Limited
20/03/202411:00UK RegulatoryOKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventLSE:OKYOOkyo Pharma Limited
09/02/202412:36InvestorsHub NewsWireOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainLSE:OKYOOkyo Pharma Limited
09/02/202412:00UK RegulatoryOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainLSE:OKYOOkyo Pharma Limited
31/01/202412:00UK RegulatoryOKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory BoardLSE:OKYOOkyo Pharma Limited
22/05/202308:15UK RegulatoryOKYO Pharma Limited London Stock Exchange DelistingLSE:OKYOOkyo Pharma Limited
22/05/202308:00UK RegulatoryLondon Stock Exchange Notice Cancellation - OKYO PHARMA LIMITEDLSE:OKYOOkyo Pharma Limited
19/05/202311:22Alliance NewsAlliance NewsIN BRIEF: Okyo Pharma to move shares to New York with London delistingLSE:OKYOOkyo Pharma Limited
19/05/202308:00RNS Non-RegulatoryOKYO Pharma Limited ADS Program collapseLSE:OKYOOkyo Pharma Limited
15/05/202307:00UK RegulatoryOKYO Pharma Limited Change of Record Time and Last Day of DealingsLSE:OKYOOkyo Pharma Limited
11/05/202314:27Alliance NewsAlliance NewsIN BRIEF: Okyo Pharma delays delisting from London trading to May 22LSE:OKYOOkyo Pharma Limited
11/05/202312:00RNS Non-RegulatoryOKYO Pharma Limited Webull Corporate Communications Service PlatformLSE:OKYOOkyo Pharma Limited
11/05/202307:00UK RegulatoryOKYO Pharma Limited Change of Delisting Date to 22 May 2023LSE:OKYOOkyo Pharma Limited
03/05/202313:00UK RegulatoryOKYO Pharma Limited Result of MeetingLSE:OKYOOkyo Pharma Limited
03/05/202307:00RNS Non-RegulatoryOKYO Pharma Limited Presentation on OK-101 at ASCRSLSE:OKYOOkyo Pharma Limited
02/05/202320:16Alliance NewsAlliance NewsTRADING UPDATES: Knights Group buys St James Law and Baines WilsonLSE:OKYOOkyo Pharma Limited
02/05/202307:00UK RegulatoryOKYO Pharma Limited First-Patient First-Visit for Phase 2 TrialLSE:OKYOOkyo Pharma Limited
25/04/202316:19Alliance NewsAlliance NewsTRADING UPDATES: Eckoh expects profit up; LXi REIT refinances facilityLSE:OKYOOkyo Pharma Limited
25/04/202307:00UK RegulatoryOKYO Pharma Limited Activation of First Clinical Trial Site in the U.SLSE:OKYOOkyo Pharma Limited
05/04/202307:00UK RegulatoryOKYO Pharma Limited NOTICE OF GENERAL MEETING AND CIRCULAR PUBLICATIONLSE:OKYOOkyo Pharma Limited
04/04/202309:08Alliance NewsAlliance NewsOkyo Pharma applies to delist from London Stock Exchange due to costsLSE:OKYOOkyo Pharma Limited
04/04/202307:00UK RegulatoryOKYO Pharma Limited Notice Of Intention To Delist From The LSELSE:OKYOOkyo Pharma Limited
30/03/202307:00UK RegulatoryOKYO Pharma Limited Director Acquires SharesLSE:OKYOOkyo Pharma Limited
29/03/202307:00UK RegulatoryOKYO Pharma Limited Director acquires sharesLSE:OKYOOkyo Pharma Limited
24/03/202307:00UK RegulatoryOKYO Pharma Limited Director/PDMR ShareholdingLSE:OKYOOkyo Pharma Limited
16/03/202307:01RNS Non-RegulatoryOKYO Pharma Limited Listing of Trial on the ClinicalTrials.gov WebsiteLSE:OKYOOkyo Pharma Limited
 Showing the most relevant articles for your search:LSE:OKYO

Your Recent History

LSE
SYME
Supply@me Capital
LSE
TXP
Touchstone Exploration
LSE
AAU
Ariana Resources
LSE
MIN
Minoan
LSE
PANR
Pantheon Resources
LSE
BIRD
Blackbird
LSE
AAZ
Anglo Asian Mining
LSE
GSK
Gsk
LSE
BOO
Boohoo
LSE
UKOG
Uk Oil & Gas
LSE
GSF
Gore Street Energy Storage
LSE
GENF
Genflow Biosciences
LSE
TRIN
Trinity Exploration & Pr...
LSE
JDW
Wetherspoon ( J.d.)
LSE
GKP
Gulf Keystone Petroleum
LSE
APTA
Aptamer
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved